CMO/CDMO Biotechnology Market to Reach USD 37.53 Billion by 2033 as Biologics Outsourcing, Integrated Service Models, and U.S.-Asia Capacity Expansion Accelerate Contract Manufacturing Demand

May 3, 2026 - The global CMO/CDMO biotechnology market reached USD 14.32 billion in 2024, up from USD 12.74 billion in 2023, and is projected to reach USD 37.53 billion by 2033, advancing at a CAGR of 11.3% during 2026-2033. That represents an incremental revenue opportunity of roughly USD 23.21 billion over the forecast period. The market is expanding on the back of rising demand for biologics, biosimilars, cell and gene therapies, and more complex development programs that smaller and mid-sized biotech companies increasingly prefer to outsource rather than build in-house. Datam Intelligence notes that demand for novel biologics and biosimilars, capacity expansion, and integrated development-to-manufacturing models are now central to market growth.

Request Executive Sample | Market Intelligence: https://www.datamintelligence.com/download-sample/cmo-cdmo-biotechnology-market?kailas

Commercially, this is no longer a market defined only by overflow manufacturing. It is becoming an operating model for biotech innovation itself. Sponsors increasingly want partners that can handle cell line development, process development, analytical support, clinical supply, fill-finish, and commercial manufacturing under a single quality and regulatory framework. That shift is lifting the strategic value of integrated CDMO offerings, even though standalone services still hold the larger current share. Datam Intelligence says standalone services accounted for 56.45% of the market in 2024, while integrated services were the faster-growing segment, reflecting stronger demand for end-to-end execution.

Recent Developments

1. In March 2026, Samsung Biologics completed its acquisition of GSK's manufacturing facility in Rockville, Maryland, establishing its first manufacturing presence in the United States. The move is significant because it gives one of the world's largest biologics CDMOs a local U.S. manufacturing base at a time when customers increasingly want regional redundancy and closer proximity to commercial markets.

2. In March 2026, Lonza and Genetix Biotherapeutics extended their commercial manufacturing agreement for ZYNTEGLO, with Lonza expanding capacity in Houston to support growing demand for the gene therapy. This matters because it shows that outsourced biologics manufacturing demand is not confined to early development. It is moving into long-duration commercial supply relationships for complex advanced therapies.

3. In March 2026, FUJIFILM Biotechnologies introduced ShunzymeX precision purification technology, designed to simplify downstream processing for complex biologics. The importance of this announcement lies in process efficiency. As biologic molecules become more complex, downstream processing becomes a bigger economic and technical bottleneck, making purification innovation increasingly valuable inside CDMO service models.

4. In January 2026, WuXi Biologics launched PatroLab, a digital twin platform for bioprocess development and manufacturing that combines real-time monitoring with process analytical technology. This is commercially important because digitalization is becoming a competitive differentiator in CDMO operations, especially where sponsors are looking for faster scale-up, better predictability, and stronger batch consistency.

Segment Analysis

By service type, standalone services remain the largest revenue segment, accounting for 56.45% of the market in 2024. The segment's strength reflects continued outsourcing of specialized activities such as analytical testing, formulation development, regulatory support, and development-stage process work. These services remain commercially important because they let biotech companies access high-skill capabilities without committing to a single integrated partner too early in a program.

The more strategically attractive segment, however, is integrated services. This is where many of the market's strongest future revenue pools are forming. Datam Intelligence identifies integrated services as the faster-growing segment because biotech and pharma sponsors increasingly prefer one partner that can move a molecule from development through commercial manufacturing with fewer tech-transfer risks and shorter timelines. In business terms, integrated models are attractive because they improve customer retention, expand wallet share, and make CDMOs harder to replace once a program scales.

By product, the market spans small molecules and large molecules, but the commercial gravity is increasingly shifting toward large molecules given the growth of monoclonal antibodies, recombinant proteins, biosimilars, and advanced biologics. Datam Intelligence also segments the market by company size into small, mid-sized, and large customers, by scale of operation into preclinical, clinical, and commercial stages, and by expression system into mammalian and microbial platforms. In practical terms, the best-margin opportunities are concentrated where complex biologics require mammalian systems, clinical-to-commercial scale-up, and integrated development support.

Regional Analysis

North America remains the leading regional market, accounting for 41.38% of global revenue in 2024, according to Datam Intelligence. The region benefits from a dense biotech ecosystem, large biologics pipelines, strong regulatory infrastructure, and heavy outsourcing by both established pharma companies and emerging biotech firms. The United States is the core growth engine inside that regional base. Its importance is reinforced by continued facility investment from leading CDMOs, including Samsung Biologics' Rockville acquisition and Lonza's expanded U.S. footprint in Vacaville and Houston.

Asia-Pacific is the fastest-growing regional market and is expected to expand at a 12.7% CAGR, supported by growing biologics demand, improving healthcare infrastructure, and rising local manufacturing capacity. Japan is strategically important because policy makers are explicitly trying to strengthen domestic bio CMO and CDMO capability. METI materials state that the global bio CMO/CDMO market has continued to grow and that Japan's presence remains relatively limited versus global leaders, which is precisely why local capacity building has become a policy priority. That gives Japan significance not only as a demand market, but as a strategic manufacturing and ecosystem-development market for future outsourced biologics production.

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=cmo-cdmo-biotechnology-market?kailas

Company Profiles

Samsung Biologics Co., Ltd. remains one of the most important names in the market because it combines very large-scale biologics manufacturing with growing geographic reach. Its March 2026 completion of the Rockville acquisition gives it a first U.S. manufacturing site and strengthens its position as a global end-to-end biologics CDMO. Commercially, Samsung matters because scale, location flexibility, and integrated service breadth are becoming more important in winning large biologics contracts.

Lonza remains a leading benchmark in high-value biologics outsourcing. Its Vacaville site is described by the company as one of the world's largest biologics sites dedicated to late-stage clinical and commercial mammalian manufacturing, with 332,000 liters of capacity. Lonza's March 2026 extension of the ZYNTEGLO manufacturing agreement also shows why it matters commercially: it is positioned strongly where long-term commercial biologics supply meets complex process execution.

Catalent remains highly relevant because it continues to market integrated biologics CDMO services through its OneBio suite, which spans development through clinical and commercial supply, including fill-finish and packaging. Catalent matters because the market is rewarding CDMOs that can simplify and de-risk biologics programs rather than offer only isolated capabilities.

FUJIFILM Biotechnologies is increasingly important because it combines biologics manufacturing scale with process innovation. Its March 2026 launch of ShunzymeX and its recognition as a 2026 CDMO Leadership Award winner in biologics innovation reinforce its commercial relevance in advanced downstream processing and sponsor-facing service quality.

Analyst View

The strongest revenue pools in this market are forming where large-molecule demand, integrated service delivery, and commercial-scale biologics capacity intersect. That makes integrated services, mammalian expression systems, and late-stage clinical-to-commercial manufacturing the most attractive parts of the market over the medium term. The most compelling opportunities are likely to sit with CDMOs that can combine process development, regulatory support, manufacturing scale, and digital process control in one operating model.

Competition is intensifying around execution quality, not just available capacity. The likely winners will be the companies that can offer customers faster scale-up, stronger regulatory reliability, regional flexibility, and fewer handoffs across development and manufacturing. In this market, the next wave of value creation will come from making biologics outsourcing easier to trust, easier to scale, and easier to commercialize globally.

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.

This release was published on openPR.